Annual EBITDA
$240.29 M
+$94.13 M+64.40%
31 December 2023
Summary:
Amphastar Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $240.29 million, with the most recent change of +$94.13 million (+64.40%) on 31 December 2023. During the last 3 years, it has risen by +$210.10 million (+695.91%). AMPH annual EBITDA is now at all-time high.AMPH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$68.81 M
-$4.18 M-5.73%
30 September 2024
Summary:
Amphastar Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $68.81 million, with the most recent change of -$4.18 million (-5.73%) on 30 September 2024. Over the past year, it has dropped by -$22.10 million (-24.31%). AMPH quarterly EBITDA is now -24.31% below its all-time high of $90.91 million, reached on 30 September 2023.AMPH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$276.85 M
-$22.10 M-7.39%
30 September 2024
Summary:
Amphastar Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $276.85 million, with the most recent change of -$22.10 million (-7.39%) on 30 September 2024. Over the past year, it has increased by +$52.03 million (+23.14%). AMPH TTM EBITDA is now -7.39% below its all-time high of $298.95 million, reached on 30 June 2024.AMPH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AMPH EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.4% | -24.3% | +23.1% |
| 3 y3 years | +695.9% | +54.0% | +254.9% |
| 5 y5 years | +3416.7% | +901.8% | +247.9% |
AMPH EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +695.9% | -24.3% | +126.5% | -7.4% | +254.9% |
| 5 y | 5 years | at high | +3416.7% | -24.3% | >+9999.0% | -7.4% | +826.6% |
| alltime | all time | at high | +1292.3% | -24.3% | +1133.2% | -7.4% | +1868.5% |
Amphastar Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $68.81 M(-5.7%) | $276.85 M(-7.4%) |
| June 2024 | - | $73.00 M(+3.6%) | $298.95 M(+11.0%) |
| Mar 2024 | - | $70.45 M(+9.1%) | $269.38 M(+12.1%) |
| Dec 2023 | $240.29 M(+64.4%) | $64.59 M(-29.0%) | $240.29 M(+6.9%) |
| Sept 2023 | - | $90.91 M(+109.3%) | $224.82 M(+36.8%) |
| June 2023 | - | $43.43 M(+5.0%) | $164.40 M(+8.6%) |
| Mar 2023 | - | $41.36 M(-15.8%) | $151.34 M(+3.5%) |
| Dec 2022 | $146.16 M(+31.0%) | $49.11 M(+61.1%) | $146.16 M(+11.8%) |
| Sept 2022 | - | $30.49 M(+0.4%) | $130.71 M(-9.8%) |
| June 2022 | - | $30.38 M(-16.0%) | $144.91 M(+6.8%) |
| Mar 2022 | - | $36.18 M(+7.5%) | $135.70 M(+21.6%) |
| Dec 2021 | $111.56 M(+269.5%) | $33.66 M(-24.7%) | $111.56 M(+43.0%) |
| Sept 2021 | - | $44.68 M(+111.1%) | $78.01 M(+65.1%) |
| June 2021 | - | $21.17 M(+75.8%) | $47.25 M(+54.8%) |
| Mar 2021 | - | $12.04 M(>+9900.0%) | $30.53 M(+1.1%) |
| Dec 2020 | $30.19 M(-62.9%) | $116.00 K(-99.2%) | $30.19 M(-18.3%) |
| Sept 2020 | - | $13.92 M(+212.9%) | $36.93 M(+23.6%) |
| June 2020 | - | $4.45 M(-62.0%) | $29.88 M(-67.4%) |
| Mar 2020 | - | $11.70 M(+70.6%) | $91.64 M(+12.5%) |
| Dec 2019 | $81.47 M(+1092.3%) | $6.86 M(-0.2%) | $81.47 M(+2.4%) |
| Sept 2019 | - | $6.87 M(-89.6%) | $79.58 M(-0.0%) |
| June 2019 | - | $66.21 M(+4230.4%) | $79.58 M(+491.9%) |
| Mar 2019 | - | $1.53 M(-69.2%) | $13.44 M(+96.8%) |
| Dec 2018 | $6.83 M | $4.97 M(-27.7%) | $6.83 M(+40.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $6.87 M(+9060.0%) | $4.86 M(+1627.8%) |
| June 2018 | - | $75.00 K(-101.5%) | $281.00 K(-96.2%) |
| Mar 2018 | - | -$5.08 M(-269.9%) | $7.46 M(-58.7%) |
| Dec 2017 | $17.89 M(-41.0%) | $2.99 M(+30.3%) | $18.05 M(+28.1%) |
| Sept 2017 | - | $2.30 M(-68.3%) | $14.10 M(-35.3%) |
| June 2017 | - | $7.25 M(+31.4%) | $21.80 M(-22.8%) |
| Mar 2017 | - | $5.52 M(-670.4%) | $28.22 M(-7.0%) |
| Dec 2016 | $30.33 M(+682.8%) | -$967.00 K(-109.7%) | $30.33 M(-32.8%) |
| Sept 2016 | - | $10.00 M(-26.9%) | $45.12 M(+31.0%) |
| June 2016 | - | $13.67 M(+79.3%) | $34.44 M(+144.1%) |
| Mar 2016 | - | $7.63 M(-44.8%) | $14.11 M(+264.1%) |
| Dec 2015 | $3.88 M(-225.4%) | $13.82 M(-2129.4%) | $3.88 M(-130.9%) |
| Sept 2015 | - | -$681.00 K(-89.8%) | -$12.54 M(-19.9%) |
| June 2015 | - | -$6.66 M(+155.8%) | -$15.65 M(+129.6%) |
| Mar 2015 | - | -$2.60 M(+0.5%) | -$6.82 M(+120.6%) |
| Dec 2014 | -$3.09 M(-109.9%) | -$2.59 M(-31.8%) | -$3.09 M(-151.8%) |
| Sept 2014 | - | -$3.80 M(-274.6%) | $5.96 M(-56.0%) |
| June 2014 | - | $2.18 M(+93.7%) | $13.56 M(-49.5%) |
| Mar 2014 | - | $1.12 M(-82.6%) | $26.85 M(-14.1%) |
| Dec 2013 | $31.26 M(-18.1%) | $6.46 M(+70.1%) | $31.26 M(+26.1%) |
| Sept 2013 | - | $3.80 M(-75.4%) | $24.80 M(+18.1%) |
| June 2013 | - | $15.46 M(+179.4%) | $21.00 M(+279.4%) |
| Mar 2013 | - | $5.54 M | $5.54 M |
| Dec 2012 | $38.16 M(-289.3%) | - | - |
| Dec 2011 | -$20.15 M | - | - |
FAQ
- What is Amphastar Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Amphastar Pharmaceuticals?
- What is Amphastar Pharmaceuticals annual EBITDA year-on-year change?
- What is Amphastar Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Amphastar Pharmaceuticals?
- What is Amphastar Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Amphastar Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Amphastar Pharmaceuticals?
- What is Amphastar Pharmaceuticals TTM EBITDA year-on-year change?
What is Amphastar Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AMPH is $240.29 M
What is the all time high annual EBITDA for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $240.29 M
What is Amphastar Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, AMPH annual earnings before interest, taxes, depreciation & amortization has changed by +$94.13 M (+64.40%)
What is Amphastar Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AMPH is $68.81 M
What is the all time high quarterly EBITDA for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $90.91 M
What is Amphastar Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, AMPH quarterly earnings before interest, taxes, depreciation & amortization has changed by -$22.10 M (-24.31%)
What is Amphastar Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AMPH is $276.85 M
What is the all time high TTM EBITDA for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $298.95 M
What is Amphastar Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, AMPH TTM earnings before interest, taxes, depreciation & amortization has changed by +$52.03 M (+23.14%)